drugset / Press release
STOP-HAE: A Phase 3 Study of ADX-324 in HAE (STOP-HAE)
2025-07-08 · ADARx Pharmaceuticals, Inc. · original adarx.com ↗
Recruiting Status: Active, not recruiting Age: 18 – 65 Years Old STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema Learn More
The release as fetched from its publisher. adarx.com ↗